

A Pharmaceutical Strategy for Europe

2021/2013(INI) - 08/11/2021 - Committee report tabled for plenary, single reading

The Committee on the Environment, Public Health and Food Safety adopted an own-initiative report by Dolors MONTSERRAT (EPP, ES) on a pharmaceutical strategy for Europe.

Health is fundamental to the well-being of Europeans and equitable access to healthcare is a cornerstone of the EU and Member States' national health policies. 40 % of medicinal end products marketed in the EU originate in non-EU countries, while 60 % to 80 % of active pharmaceutical ingredients are produced in China and India. The report noted that the disruption of the global supply chain ensuing from the COVID-19 pandemic has highlighted the EU's dependency on third countries in the health sector.

Putting patients at the centre of all health policies

Members regretted the disparities in access to high-quality healthcare services, including access to medicinal products, among Member States and also among different regions within Member States. They called for national and EU measures, including legislative measures where appropriate, to address these disparities and guarantee the right of patients to universal, affordable, effective, safe and timely access to essential and innovative medicines.

Antimicrobial resistance (AMR)

Considering that AMR constitutes a serious threat to public health, Members recommend to the Commission to introduce an EU therapeutic guide for antimicrobials, setting up traceable antimicrobial use reduction targets at EU level, and that communication campaigns on AMR be coordinated through a single calendar at EU level.

Research in pharmaceuticals

The report called on the Commission to assess, and revise where appropriate, the system of incentives to promote research into and the development of new medicines for unmet diagnostic and therapeutic needs, prioritising public interests and patient safety when assessing projects promoted by the pharmaceutical industry to combat cancers, including paediatric cancers. They suggested that an EU framework should be created to guide and regularly evaluate the implementation of national plans to fight these diseases.

Pricing and costs of pharmaceuticals

Members called on the Commission to:

- promote dialogue with the Member States and all relevant stakeholders to promote '**Made in Europe**' pharmaceuticals by strengthening manufacturing and supply resilience;
- promote **information sharing** among Member States on net medicine prices through the European Integrated Price Information Database (EURIPID) collaboration;
- introduce measures to increase **transparency** in the area of research into and the development and production of medicinal products;
- address the **root causes of shortages** of pharmaceuticals and propose sustainable solutions and mitigations plans;

- be alert to **anti-competitive conduct** and investigate anti-competitive practices in the pharmaceutical industry.

Access to medicines in the EU

Members are concerned that the accessibility and affordability of medicines remain a challenge for national health systems, and that innovative medicines are expensive or in certain Member States not even brought to the market for commercial reasons. In this regard, the Commission is called on to assess policy options that help guarantee that centrally authorised medicines are marketed in all Member States and not just in those that are commercially interesting.

Structured dialogue with stakeholders

Members considered that a wider political High Level Pharmaceutical **Forum** is needed, bringing together policymakers and other relevant stakeholders in the healthcare supply chain, in order to share the lessons learnt from the COVID-19 emergency situation and to establish an effective policy framework to prevent shortages in the long term, enable access to medicines for patients, reduce delays, and ensure competitiveness and innovation.

Sustainable and environmentally friendly medicines

Lastly, the report stressed the need for the pharmaceutical industry to be environmentally friendly and climate-neutral throughout the lifecycles of medicinal products, while ensuring access to safe and effective pharmaceutical treatments for patients. The Commission is urged to ensure quality environmental sustainability standards for active pharmaceutical ingredients imported from non-EU countries and to address the problem of pharmaceutical household waste, through measures to **reduce packaging**.